

# Tuberculosis profile: Romania

Population 2019: 19 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	13 000 (11 000-15 000)	66 (56-76)
HIV-positive TB incidence	240 (190-290)	1.2 (0.99-1.5)
MDR/RR-TB incidence**	630 (490-770)	3.2 (2.6-4)
HIV-negative TB mortality	790 (790-800)	4.1 (4.1-4.1)
HIV-positive TB mortality	38 (27-52)	0.2 (0.14-0.27)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	2.7% (2.3-3.1)
Previously treated cases	13% (11-15)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	7% (6-8)

## TB case notifications, 2019

Total new and relapse	11 083
- % tested with rapid diagnostics at time of diagnosis	25%
- % with known HIV status	86%
- % pulmonary	86%
- % bacteriologically confirmed ^	85%
- % children aged 0-14 years	4%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	28%
- % men	68%
Total cases notified	11 633

## TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	179	1.9%
- on antiretroviral therapy	161	90%

## Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	89%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	87%
Laboratory-confirmed cases - MDR/RR-TB ^^	371
Patients started on treatment - MDR/RR-TB ^^	389
Laboratory-confirmed cases - XDR-TB ^^	36
Patients started on treatment - XDR-TB ^^	36
MDR/RR-TB cases tested for resistance to any fluoroquinolone	144

## Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	84%	11 271
Previously treated cases, excluding relapse, registered in 2018	48%	481
HIV-positive TB cases registered in 2018	58%	216
MDR/RR-TB cases started on second-line treatment in 2017	46%	398
XDR-TB cases started on second-line treatment in 2017	0%	57

## TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



## Treatment success rate



## Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (100-100)

## TB financing

National TB budget, 2020 (US\$ millions)	13
- Funding source, domestic	58%
- Funding source, international	23%
- unfunded	19%

\* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)